March 6 (Reuters) - Johnson & Johnson JNJ.N said on Thursday it will stop a late-stage study of its add-on treatment for major depressive disorder due to insufficient efficacy in the target patient population.
(Reporting by Puyaan Singh in Bengaluru; Editing by Arun Koyyur)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.